文献速递真实世界研究与卫生经济流行病学与生物统计

四种太平洋岛国轮状病毒、肺炎球菌结合及人乳头瘤病毒疫苗接种的成本效果模型评估

Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study.
PubMed 文献 · PLoS Med · 2026-02-12

该研究采用比例结果模型,从卫生系统视角评估萨摩亚、汤加、图瓦卢和瓦努阿图自2021年起十年接种轮状病毒疫苗、肺炎球菌结合疫苗和人乳头瘤病毒疫苗的成本效果与预算影响。结果显示,三国同时引入三种疫苗可在接种队列终生避免超过1000例死亡,每避免一个伤残调整生命年的成本为各国人均GDP的42%–73%(PAHO循环基金价格)或15%–58%(低价疫苗),但预算影响可达2019年疫苗预算的359%–1368%。结论认为在开发伙伴支持下可能具有成本效果,但免疫规划预算面临显著压力。

要点

  • 四国同时引入三种疫苗可在接种队列终生避免超过1000例死亡。
  • 每避免一个DALY的成本为各国人均GDP的42%–73%(PAHO价格)或15%–58%(低价疫苗)。
  • 预算影响为2019年疫苗预算的359%(萨摩亚)至1368%(瓦努阿图),低价疫苗为149%至775%。

核心结论

  • 在开发伙伴支持下,萨摩亚、汤加、图瓦卢和瓦努阿图引入HPV疫苗、PCV和RVV可能具有成本效果,取决于支付意愿阈值。
  • 三种疫苗的纳入将给免疫规划预算带来 considerable 负担,财务可持续性需要增加免疫预算并谈判可负担的疫苗价格。

研究设计与样本

  • 采用比例结果模型,从卫生系统视角评估四个国家疫苗引入的成本效果。
  • 使用国家特异性数据并补充区域和全球估计,模拟自2021年起10年接种规划。
  • 成本和结局(伤残调整生命年)按终生时间 horizon 汇总,并以3%贴现。
  • 疫苗剂量成本基于泛美卫生组织(PAHO)循环基金价格,并探索更低价格产品。

主要发现

  • 所有国家引入三种疫苗可在接种队列终生避免超过1000例死亡。
  • 每避免一个DALY的成本在PAHO循环基金价格下为各国人均GDP的42%至73%,低价疫苗为15%至58%。
  • 预算影响范围为2019年疫苗预算的359%(萨摩亚)至1368%(瓦努阿图),低价疫苗为149%(萨摩亚)至775%(瓦努阿图)。
  • 成本效果结果对疾病负担、贴现率、疫苗效力和规划成本最为敏感。

临床怎么用

  • 可为四个太平洋岛国决策同时引入三种疫苗提供本地化成本效果与预算影响证据。
  • 提示需结合支付意愿阈值判断成本效果,并提前规划免疫预算增加与低价疫苗谈判。

局限性

  • 研究依赖斐济的数据来推断疾病负担,因为国家特异性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of rotavirus vaccine (RVV), pneumococcal conjugate vaccine (PCV) and human papillomavirus vaccine (HPVV) has been slow in Pacific Island Countries, particularly among middle-income countries. To assist decision-making on the simultaneous introduction of these three vaccines, cost-effectiveness and budget impact evaluations were undertaken in Samoa, Tonga, Tuvalu and Vanuatu, using locally relevant data. METHODS AND FINDINGS: A proportionate outcomes model was used to evaluate vaccine introduction in each country from a health systems perspective, using country-specific data supplemented with regional and global estimates. A 10-year vaccination program was modelled from 2021, with costs and outcomes (disability-adjusted life years [DALYs]) summed over a life-time horizon and discounted at 3%. Vaccine dose costs were based on Pan American Health Organization (PAHO) Revolving Fund prices, with lower-priced products also explored. Introduction of all three vaccines in all countries could prevent over 1,000 deaths over the lifetimes of the vaccinated cohorts. The cost per DALY averted at PAHO Revolving Fund prices ranged from 42% to 73% of the per capita gross domestic product (GDP) in each country, and 15% to 58% for lower-priced vaccines. The budget impact ranged from 359% (Samoa) to 1,368% (Vanuatu) of the 2019 vaccine budgets, and 149% (Samoa) to 775% (Vanuatu) for lower-priced vaccines. Cost-effectiveness results were most sensitive to disease burden, discount rate, vaccine efficacy, and program costs. A limitation of our study is the reliance on data from Fiji to inform disease burden, as availability of country-specific data was limited. CONCLUSIONS: With development partner support, introduction of HPVV, PCV and RVV may represent good value for money in Samoa, Tonga, Tuvalu and Vanuatu, depending on willingness to pay thresholds. However, inclusion of these three vaccines will place considerable burden on immunisation budgets. Financial sustainability requires increases in immunisation budgets and negotiation of affordable vaccine prices. This analysis provides evidence of the benefit of introducing new vaccines, but shows the importance of affordable pricing to ensure sustainability for small Pacific Island countries.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Carvalho N, Watts E, Oliver VL, et al. Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study. PLoS Med. 2026. PMID: 41678506. doi:10.1371/journal.pmed.1004604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。